INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Hyliion Holdings Corp.

Hyliion (HYLN) is facing a securities-fraud investigation by Pomerantz LLP, following allegations that a VFG Holdings non-binding LOI for up to 250 KARNO cores (up to ~$133M potential revenue) may not reflect meaningful commercial validation. After a Pelican Way Research short report questioned the LOI’s substance, Hyliion shares fell $1.27 (-17.2%) to close at $6.10 on June 23, 2026, with the LOI reportedly comprising ~one-third of its $400M+ pipeline. The investigation heightens perceived fraud/legal risk around the Company’s reported pipeline and disclosures.

Analysis

The core market mechanism is not the lawsuit itself; it is the reset in credibility on a name whose equity value depends on future contract conversion and external financing. Once a single LOI is challenged as non-economic, every remaining pipeline item gets repriced as low-conviction until management proves funded customers, deposits, or revenue recognition that survives diligence. For a pre-scale hardware company, that usually means a higher cost of capital, slower partner adoption, and a tighter window for dilution before the next raise.

The second-order loser is the broader stationary power / alternative engine complex: investors will demand harder proof of order quality from peers that market “pipeline” rather than backlog. That is a relative negative for smaller clean-tech or distributed generation names with customer concentration and weak balance sheets, while incumbents with bankable installed bases and service revenue should benefit from a credibility premium. If HYLN is forced to spend management time on defense and disclosure rather than commercialization, the operational lag can persist for 1-3 quarters even if the stock stabilizes.

Near term, the stock can overshoot on both sides because these cases trade on narrative flow, not fundamentals. The real falsifier is not legal commentary but evidence of funded demand: contract deposits, conversion of LOIs into binding orders, or guidance that implies shipments and cash receipts rather than projections. Absent that, the path of least resistance over 1-3 months is continued multiple compression; over 6-18 months the risk is dilution or strategic retrenchment if commercialization remains unproven.

The contrarian risk is that the market may already be discounting near-zero credibility, making outright shorting unattractive after the initial flush. Any genuine commercial validation or financing event could trigger a sharp squeeze because the float is likely held by event-driven and retail participants with limited patience. This is a classic situation where the thesis is right but timing is dangerous unless you have a clear catalyst calendar and borrow/liquidity support.

Key Decisions for Investors

• Avoid chasing HYLN weakness intraday; if you want exposure, wait for a reflexive bounce into the prior breakdown area and use tight risk limits. Best executed as a 1-3 month short or put spread only if borrow is available and liquidity is sufficient.
• Prefer HYLN Jan/Apr put spreads over outright short common stock for convexity with defined risk; target a scenario where commercial proof does not appear and the market re-prices the pipeline as optionality with dilution risk.
• Pair trade: short HYLN vs long a higher-quality distributed power incumbent such as CMI or BE over the next 1-3 months to isolate credibility and execution risk rather than sector beta.
• Set an alert for any announcement of binding orders, customer deposits, or funding tied to the referenced counterparty; that would be the primary falsifier and could force a 20-30% squeeze quickly.
• If HYLN raises equity or convertible capital on weak terms, add to the bearish view immediately; dilution at this stage would be a stronger signal than the headline litigation overhang.